Aspirin for the primary prevention of cardiovascular events: Recommendation and rationale

被引：239

作者：

Berg, AO ^{[1
]}

Allan, JD

Frame, PS

Homer, CJ

Johnson, MS

Klein, JD

Lieu, TA

Mulrow, CD

Orleans, CT

Peipert, JF

Pender, NJ

Siu, AL

Teutsch, SM

Westhoff, C

Woolf, SH

机构：

[1] Univ Washington, Seattle, WA 98195 USA

[2] Univ Texas, Hlth Sci Ctr, San Antonio, TX 78284 USA

[3] TriCty Family Med, Cohocton, NY USA

[4] Univ Rochester, Sch Med, Rochester, NY 14627 USA

[5] Natl Initiat Childrens Healthcare Qual, Boston, MA USA

[6] Univ Med & Dent New Jersey, New Jersey Med Sch, Newark, NJ 07103 USA

[7] Harvard Univ, Pilgrim Hlth Care, Boston, MA 02115 USA

[8] Harvard Univ, Sch Med, Boston, MA 02115 USA

[9] Audie L Murphy Mem Vet Adm Med Ctr, San Antonio, TX 78284 USA

[10] Robert Wood Johnson Fdn, Princeton, NJ 08540 USA

[11] Women & Infants Hosp Rhode Isl, Providence, RI 02908 USA

[12] Univ Michigan, Ann Arbor, MI 48109 USA

[13] CUNY Mt Sinai Sch Med, New York, NY 10029 USA

[14] Mt Sinai Med Ctr, New York, NY 10029 USA

[15] Merck & Co Inc, West Point, PA USA

[16] Columbia Univ Coll Phys & Surg, New York, NY 10032 USA

[17] Virginia Commonwealth Univ, Med Coll Virginia, Fairfax, VA USA

来源：

ANNALS OF INTERNAL MEDICINE | 2002年 / 136卷 / 02期

关键词：

D O I：

10.7326/0003-4819-136-2-200201150-00015

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

This statement summarizes the recommendation of the third U.S. Preventive Services Task Force (USPSTF) for aspirin for the primary prevention of cardiovascular events, as well as the supporting scientific evidence. The complete information on which this statement is based, including evidence tables and references, can be found in a companion article in this issue. Copies of this document, the summary of the evidence, and the systematic evidence review can be obtained through the USPSTF Web site (www.ahrq.gov/clinic/uspstfix.htm) and in print: through the Agency for Healthcare Research and Quality Publications Clearinghouse (800-358-9295).

引用

页码：157 / 160

页数：4

共 16 条

[1] COLLABORATIVE OVERVIEW OF RANDOMIZED TRIALS OF ANTIPLATELET THERAPY .1. PREVENTION OF DEATH, MYOCARDIAL-INFARCTION, AND STROKE BY PROLONGED ANTIPLATELET THERAPY IN VARIOUS CATEGORIES OF PATIENTS [J].

ALTMAN, R ;

CARRERAS, L ;

DIAZ, R ;

FIGUEROA, E ;

PAOLASSO, E ;

PARODI, JC ;

CADE, JF ;

DONNAN, G ;

EADIE, MJ ;

GAVAGHAN, TP ;

OSULLIVAN, EF ;

PARKIN, D ;

RENNY, JTG ;

SILAGY, C ;

VINAZZER, H ;

ZEKERT, F ;

ADRIAENSEN, H ;

BERTRANDHARDY, JM ;

BRAN, M ;

DAVID, JL ;

DRICOT, J ;

LAVENNEPARDONGE, E ;

LIMET, R ;

LOWENTHAL, A ;

MORIAU, M ;

SCHAPIRA, S ;

SMETS, P ;

SYMOENS, J ;

VERHAEGHE, R ;

VERSTRAETE, M ;

ATALLAH, A ;

BARNETT, H ;

BATISTA, R ;

BLAKELY, J ;

CAIRNS, JA ;

COTE, R ;

CROUCH, J ;

EVANS, G ;

FINDLAY, JM ;

GENT, M ;

LANGLOIS, Y ;

LECLERC, J ;

NORRIS, J ;

PINEO, GF ;

POWERS, PJ ;

ROBERTS, R ;

SCHWARTZ, L ;

SICURELLA, J ;

TAYLOR, W ;

THEROUX, P .

BMJ-BRITISH MEDICAL JOURNAL, 1994, 308 (6921) :81-100

[2]

*AM DIAB ASS, 2001, DIABETES CARE S1, V24, pS62

[3]

ANDERSON G, 1994, CANADIAN TASK FORCE, P680

[4] Aspirin: benefit and risk in thromboprophylaxis [J].

Dickinson, JP ;

Prentice, CRM .

QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 1998, 91 (08) :523-538

[5] Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension:: principal results of the hypertension optimal treatment (HOT) randomised trial [J].

Hansson, L ;

Zanchetti, A ;

Carruthers, SG ;

Dahlöf, B ;

Elmfeldt, D ;

Julius, S ;

Ménard, J ;

Rahn, KH ;

Wedel, H ;

Westerling, S .

LANCET, 1998, 351 (9118) :1755-1762

[6] Aspirin for the primary prevention of cardiovascular events: A summary of the evidence for the US Preventive Services Task Force [J].

Hayden, M ;

Pignone, M ;

Phillips, C ;

Mulrow, C .

ANNALS OF INTERNAL MEDICINE, 2002, 136 (02) :161-172

[7] FINAL REPORT ON THE ASPIRIN COMPONENT OF THE ONGOING PHYSICIANS HEALTH STUDY [J].

HENNEKENS, CH .

NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (03) :129-135

[8] Aspirin as a therapeutic agent in cardiovascular disease - A statement for healthcare professionals from the American Heart Association [J].

Hennekens, CH ;

Dyken, ML ;

Fuster, V .

CIRCULATION, 1997, 96 (08) :2751-2753

[9]

HOYERT DL, 1999, DEATHS FINAL DATA 19

[10]

Meade TW, 1998, LANCET, V351, P233

← 1 2 →